Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
45.68
+0.58 (1.29%)
Dec 5, 2025, 4:00 PM EST - Market closed
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Supernus Pharmaceuticals stock have an average target of 63.25, with a low estimate of 60 and a high estimate of 65. The average target predicts an increase of 38.46% from the current stock price of 45.68.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 29, 2025.
Analyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 2 | 2 | 2 |
| Buy | 0 | 1 | 1 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +42.29% | Oct 29, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $45 → $60 | Strong Buy | Maintains | $45 → $60 | +31.35% | Oct 23, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $40 → $65 | Hold → Buy | Upgrades | $40 → $65 | +42.29% | Oct 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +37.92% | Sep 30, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $36 → $40 | Hold | Maintains | $36 → $40 | -12.43% | Aug 29, 2025 |
Financial Forecast
Revenue This Year
716.89M
from 661.82M
Increased by 8.32%
Revenue Next Year
884.36M
from 716.89M
Increased by 23.36%
EPS This Year
2.83
from 1.32
Increased by 114.56%
EPS Next Year
3.73
from 2.83
Increased by 31.81%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 745.5M | 947.6M | ||||
| Avg | 716.9M | 884.4M | ||||
| Low | 678.4M | 807.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 12.6% | 32.2% | ||||
| Avg | 8.3% | 23.4% | ||||
| Low | 2.5% | 12.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.99 | 4.49 | ||||
| Avg | 2.83 | 3.73 | ||||
| Low | 2.58 | 3.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 126.7% | 58.7% | ||||
| Avg | 114.6% | 31.8% | ||||
| Low | 95.3% | 12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.